Squire Servance is the Founder & Managing Partner of Syridex Bio. Prior to founding Syridex Bio, he served as SVP, General Counsel & Corporate Secretary at Repligen Corporation, a bioprocessing-focused life sciences company. At Repligen, Squire led the legal, corporate secretary, compliance and enterprise risk functions as well as counseled the company’s Board of Directors and senior management. He also served on Repligen’s environmental, social, and corporate governance committee. Squire joined Repligen from Baxter International, Inc. where he led the global legal team supporting their multi-billion-dollar global pharmaceuticals business. Prior to joining Baxter, Squire worked in a variety of settings including as a Director providing legal support to Dr. Reddy’s Laboratories business development team and as a life sciences attorney with Morgan, Lewis & Bockius LLP.
Squire received his J.D. from Duke University School of Law and M.B.A. with a concentration in corporate finance and a Certificate in Health Sector Management from Duke University, Fuqua School of Business. He received his B.S., with honors, with a double major in biomedical engineering and cell biology and neuroscience from Rutgers University, School of Engineering.
Interview questions:
Introduction | Please provide an introduction to Syridex Bio.
Career | Your career included stints at Repligen and Baxter. Can you share the highlights of your career?
Impetus |What was the impetus to start Syridex Bio?
Inequities | How did the pandemic impact health inequities?
Why now | Why now?
Investment Targets | What is your approach to investment targets?
Impact Investors | Who are the major impact investors addressing health inequity?
Novel Therapies |What are some of the novel therapies on your radar?
Advisory Board | Who are the members of the advisory board?
Connect with Squire on LinkedIn
Syridex Bio is an impact-driven, life sciences-focused venture creation and private equity firm investing in therapies that address the needs of underserved communities. The firm draws on deep relationships across the global pharmaceutical and biotech industries to source innovative, best-in-class clinical stage or near-clinical stage therapies. Then, it invests in development to bring to market novel drugs and treatments that might otherwise go undeveloped. Syridex Bio focuses on two primary investment strategies: venture creation, which builds sustainable companies around innovative products the firm acquires from life sciences companies and institutions; and private equity, which privatizes and creates value in undervalued public pharmaceutical and biotechnology companies.
Syridex Bio – an impact-driven, life sciences-focused investment firm targeting therapies that address the needs of underserved communities – was founded on the simple premise that everyone deserves the opportunity to live a healthy life.
The unfortunate reality is that, even in 2022, many people still do not have that opportunity. The vast disparities in health outcomes across the American healthcare system illustrate this fact.
Accelerating progress toward health equity will require unified action by a range of leaders and stakeholders, and it is increasingly clear that the investor community must play a central role. Guided by impact-minded investors – that is, investors focused on the double-bottom line of robust financial return and meaningful leaps toward health equity – the invisible hand of the market offers our most promising opportunity for broad and lasting change.
Investment in therapies that intentionally serve the underserved lays the foundation for true social justice in healthcare and opens the door to a brighter, healthier global future. Syridex Bio is leading the way toward that future.
Recent News: https://www.syridexbio.com/news-insights-2/
Edwin Warfield, CEO of citybiz.co, conducts CEO Interviews.
If you’re interested in a citybiz CEO Interview, please contact
Edwin Warfield – edwin.warfield@citybizlist.com
